Become A Wiser, More Profitable Investor

FDA's scrutiny over Novavax vaccine approval sparks debate and uncertainty

health

The FDA's delay in approving the Novavax COVID-19 vaccine has intensified debates over vaccine protocols under the Trump administration. The FDA's decision for more data and a potential new trial [5] suggests heightened scrutiny and shifting regulatory expectations, which some claim is politically influenced [11]. Concerns about vaccine safety (e.g., myocarditis) are also significant [9]. Health and Human Services Secretary Robert F. Kennedy Jr. is considering removing COVID vaccines from the CDC's childhood schedule, which has further polarized opinions [1]. Stakeholders remain divided on the necessity and morality of vaccination [14].

Helium Trades     Apr 30, 2025